{
  "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
  "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 56,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "Includes a biological pathway diagram showing B-cell maturation and a pyramid diagram showing the hierarchy of disease targeting.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/10",
  "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
  "deckJsonHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7.json",
  "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.02,
        "y": 0.53
      },
      "kind": "chart",
      "text": "B-cell maturation pathway showing NXC-201 targeting plasma cells",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e6b2512-bac8-476f-89af-d100846a653d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.3,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Anatomical mapping of NXC-201 indications to body systems",
      "attrs": null,
      "subkind": "hub-spoke",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ead2057-c453-45d0-8a39-3f8471db32f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.4,
        "y": 0.7
      },
      "kind": "diagram",
      "text": "Hierarchy of disease targeting: Other diseases, AL Amyloidosis, Overcoming neurotoxicity",
      "attrs": null,
      "subkind": "pyramid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "198f2316-80e8-43e7-9834-50db0dbc747d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.9,
        "x": 0.02,
        "y": 0.2
      },
      "kind": "list",
      "text": "Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorder, Pemphigus Vulgaris, Dermatomyositis, Ulcerative Colitis, Celiac disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis, AL Amyloidosis, Waldenström macroglobulinemia, IgA nephropathy, IgM nephropathy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3480a49-9976-45ca-8e78-571626b92ade",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Illustrative list of autoimmune diseases... Source: MedicTests. Lee, J. et al...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e95b59b-23ca-48a2-b025-16ed4e721107",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "Differentiated NXC-201 Clinical Profile Enables Indication Expansion Beyond AL Amyloidosis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fab55d7c-fd82-418b-a0d6-07e21cfe29a3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "hub-spoke",
      "slug": null,
      "matchId": "c6ebe3d0-fac0-42a9-8f6b-89b2ab5bcc1c",
      "evidence": "Anatomical diagram connecting indications to body systems",
      "confidence": 0.9
    },
    {
      "name": "pyramid",
      "slug": null,
      "matchId": "691413a6-c059-448b-9743-a279424dc35e",
      "evidence": "Hierarchical representation of disease targeting strategy",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 12,
      "from": 7,
      "beatId": "47fc5325-813f-4c11-aad6-f3be9a635757",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 7-12: N-GENIUS Platform: Novel CAR-T Construct Drives Differentiated NXC-201 Clinical Profile; NXC-201 May Be a Curative Treatment for AL Amyloidosis",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "8f6d39a4-edc9-462c-b0f9-ba792c9a198d",
      "evidence": "Slides 9-15 highlight the limitations of current treatments and potential benefits of NXC-201",
      "position": 0,
      "objective": "What are the consequences of not adopting NXC-201?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}